Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 24Lymphoid 10Other hematologic neoplasm 8Sarcoma 1Endocrine 1CNS 1

Conditions

Spinal Cord Neoplasms 1Rhabdoid Tumor 1Recurrence 1Prolactinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pituitary Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Large Granular Lymphocytic 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Choroid Plexus Neoplasms 1Burkitt Lymphoma 1Astrocytoma 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

3-Iodobenzylguanidine 3olaparib 1lutetium Lu 177 dotatate 1entrectinib 1entinostat 1Pemetrexed 1Paclitaxel 1Dexamethasone 1Calcium Dobesilate 1Cabergoline 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Calcium Dobesilate × Endocrine × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡